Bioplus-Interphex (BIX) Korea 2023, a comprehensive biotechnology convention, hosted by Korea Biotechnology Industry Organization (KoreaBIO) and Reed Exhibitions Korea (RX), will bring together global experts in all areas of biotechnology from July 12 to 14 at COEX, Seoul.

The first keynote session will highlight the conference theme, "Revamping the industry" by presenting solutions to overcome the three main issues -- high interest rates, shrinking investor sentiment, and high listing thresholds.

Additionally, emerging platform technologies such as antibody-drug conjugates (ADC), Proteolysis-targeting chimera (PROTAC) & carriers will be highlighted to discover ways to improve drug delivery. Other emerging therapies like microbiome therapies and monoclonal antibodies will also be discussed at the conference by respective experts in the field.

Other themes will include cell and gene therapies (CGT) innovations, strategic considerations for developing combination therapies, business models for developing essential medical technologies, cold chain logistics, and global clinical solutions alongside regulatory advice. 

In particular, there will be a session covering FDA trends for anti-cancer drug developers, and another session will also introduce the FDA's latest initiative on product development related to the digital health technologies (DHT) program, and highlight how R&D companies can take advantage of Inflation Reduction Act (IRA) incentives.

The impact of President Joe Biden's Executive Order on Korea’s economy will also be assessed along with a debriefing of the recently concluded  2023 BIO International Convention in Boston.

Aside from the seminar, this year's exhibition will feature more than 200 companies covering all aspects of the bio industry, from R&D to manufacturing processes, logistics, packaging, digital healthcare, and advanced bio. 

The open innovation stage will also feature 11 companies and organizations including the China Investment Promotion Administration, the Incheon Free Economic Zone (IFEZ), the British Embassy in Korea,  and Merck Korea to showcase their partnership with bio-venture start-ups.